

Radim BeÄvÄjÄ

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7191781/publications.pdf>

Version: 2024-02-01

36
papers

10,591
citations

623188

14
h-index

500791

28
g-index

37
all docs

37
docs citations

37
times ranked

14830
citing authors

#	ARTICLE	IF	CITATIONS
1	The effect of a 24-week physiotherapy and occupational therapy program in systemic sclerosis: a monocentric controlled study with follow-up.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0
2	Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study. Scientific Reports, 2021, 11, 1.	1.6	9,439
3	Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin. Biomedicines, 2021, 9, 650.	1.4	5
4	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. Annals of the Rheumatic Diseases, 2020, 79, 618-625.	0.5	71
5	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2019, 71, 1553-1570.	2.9	75
6	OP0066â€¦EFFECTIVENESS OF SPECIALIZED HAND/FACE PHYSICAL-OCCUPATIONAL THERAPY IN PATIENTS WITH SYSTEMIC SCLEROSIS â€œ PRELIMINARY RESULTS OF A ONE-YEAR CONTROLLED STUDY. , 2019, , .		0
7	S100A11 (calgizzarin) is released by circulating mononuclear cells and its elevated plasma levels distinguish systemic lupus erythematosus patients from healthy individuals. Clinical and Experimental Rheumatology, 2019, 37, 338-339.	0.4	1
8	08.48â€¦Increased body fat but decreased lean body mass and bone mineral density in myositis patients are associated with disease duration, inflammatory status, skeletal muscle involvement and physical activity. , 2017, , .		0
9	08.49â€¦Efficacy of an intensive 24-week physiotherapy programme in scleroderma patients â€œ preliminary data from a single-centre controlled study. , 2017, , .		0
10	Mapping and predicting mortality from systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1897-1905.	0.5	410
11	08.47â€¦Decreased body fat, lean body mass and bone mineral density in scleroderma patients are associated with disease activity and physical activity. , 2017, , .		0
12	AB0632â€¦Association between Interstitial Pulmonary Involvement and Microvaculature Changes in Systemic Sclerosis. Annals of the Rheumatic Diseases, 2016, 75, 1120.3-1120.	0.5	0
13	Tribbles homologue 3 stimulates canonical TGF-Î² signalling to regulate fibroblast activation and tissue fibrosis. Annals of the Rheumatic Diseases, 2016, 75, 609-616.	0.5	38
14	A3.10â€¦Plasma levels of heat shock protein 90 correlate with disease activity, lung involvement and skin fibrosis in systemic sclerosis. Annals of the Rheumatic Diseases, 2015, 74, A35.1-A35.	0.5	1
15	Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease. Rheumatology, 2015, 54, kev260.	0.9	17
16	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. Microvascular Research, 2015, 102, 19-24.	1.1	13
17	S100A4 amplifies TGF-Î²-induced fibroblast activation in systemic sclerosis. Annals of the Rheumatic Diseases, 2015, 74, 1748-1755.	0.5	52
18	A3.16â€¦Serum S100A4 correlates with skin fibrosis, lung involvement and disease activity in systemic sclerosis. Annals of the Rheumatic Diseases, 2014, 73, A48.1-A48.	0.5	1

#	ARTICLE	IF	CITATIONS
19	ABO203â€¦S100A4 Serum Levels Correlate with Disease Activity, Skin Fibrosis and Lung Involvement in Systemic Sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 871.1-871.	0.5	1
20	Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-Î² signalling to prevent fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1215-1222.	0.5	78
21	Nailfold capillaroscopy in systemic sclerosis: Data from the EULAR scleroderma trials and research (EUSTAR) database. <i>Microvascular Research</i> , 2013, 89, 122-128.	1.1	101
22	A8.3â€¦Deficit of S100A4 Prevents Joint Destruction and Systemic Bone Loss in hTNFÎ³ Mouse Model. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A58.1-A58.	0.5	0
23	Adiponectin relation to skin changes and dyslipidemia in systemic sclerosis. <i>Cytokine</i> , 2012, 58, 165-168.	1.4	29
24	Pulmonary arterial hypertension associated with systemic sclerosis in the Czech Republic. <i>Clinical Rheumatology</i> , 2012, 31, 557-561.	1.0	14
25	Polymorphism of the extrapituitary prolactin promoter and systemic sclerosis. <i>Rheumatology International</i> , 2010, 30, 1691-1693.	1.5	10
26	Prevalence of Antinucleosome Antibodies by Enzyme-Linked Immunosorbent Assays in Patients with Systemic Lupus Erythematosus and Other Autoimmune Systemic Diseases. <i>Annals of the New York Academy of Sciences</i> , 2007, 1109, 275-286.	1.8	14
27	Clinical Correlations of Potential Activity Markers in Systemic Sclerosis. <i>Annals of the New York Academy of Sciences</i> , 2005, 1051, 404-412.	1.8	15
28	Verrucous form of chilblain lupus erythematosus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2001, 15, 448-451.	1.3	14
29	European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 585-591.	0.5	83
30	Nabumetone Induces Less Gastrointestinal Mucosal Changes Than Diclofenac Retard. <i>Clinical Rheumatology</i> , 1999, 18, 273-278.	1.0	3
31	Cytokines and adhesion molecules in renal vasculitis and lupus nephritis. <i>Nephrology Dialysis Transplantation</i> , 1998, 13, 1662-1667.	0.4	68
32	Von Willebrand factor antigen and adhesive molecules in Wegener's granulomatosis and microscopic polyangiitis. <i>Clinical Rheumatology</i> , 1997, 16, 324-325.	1.0	5
33	Glycosaminoglycan polysulfuric acid (GAGPS) in osteoarthritis of the knee. <i>Osteoarthritis and Cartilage</i> , 1995, 3, 15-23.	0.6	22
34	Markers of collagen metabolism in sera of patients with various rheumatic diseases. <i>Clinica Chimica Acta</i> , 1989, 183, 243-252.	0.5	7
35	Anticollagen antibodies in patients with juvenile chronic arthritis. <i>Clinical Rheumatology</i> , 1988, 7, 378-383.	1.0	3
36	The effect of a 24-week physiotherapy and occupational therapy program in systemic sclerosis: a monocentric controlled study with follow-up. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	1